NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL
Updated: May 24, 2022
NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a first-in-human (FIH), 2-part, open-label, multi-center, Phase 1/1b safety, tolerability, pharmacokinetics (PK), and efficacy study of oral SETD2 inhibitor, EZM0414, in subjects with relapsed/refractory (R/R) Multiple Myeloma (MM) and R/R Diffuse Large B-Cell Lymphoma (DLBCL).
Sponsor
Multiple Locations
ClinicalTrials.gov Identifier: NCT05121103
Official Title: A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma
First Posted : November 16, 2021
Click here to see details on ClinicalTrials.gov
Drug: EZM0414
SETD2 Inhibitor EZM0414 (Code C185420)
EZM 0414
EZM-0414
EZM0414
SETD2 Inhibitor EZM0414
Locations
United States, Maryland
United States, Massachusetts
United States, New Jersey
United States, New York
United States, Texas
United States, Virginia
Comments